|drug2678||Quasistatic pressure-volume curve Wiki||1.00|
|drug275||Arterial blood gas Wiki||1.00|
|drug1135||Electro impedance tomography Wiki||1.00|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
There is one clinical trial.
Non-invasive ventilation can allow to avoid intubation and improve outcomes in moderate-to-severe COVID-19-associated acute respiratory distress-syndrome (ARDS). Data on NIV parameters adjustment based on expanded respiratory and gas exchange monitoring in COVID-19 associated ARDS is limited. Appropriate adjustment of the inspiratory positive airway pressure (IPAP) set as a point of the balance between minimal work of breathing (minimum point of W.Patrick scale for assessment of the accessory respiratory muscles and minimum diaphragm thickening fraction) and minimum tidal volume, and respiratory rate can decrease NIV failure in moderate-to-severe COVID-ARDS. The objective of the study is to evaluate the ability of non-invasive ventilation guided with expanded respiratory monitoring to decrease the intubation rate in in moderate-to-severe COVID-ARDS.
Description: Frequency of NIV failureMeasure: Intubation rate Time: On day 28
Description: Mortality on day 28Measure: Mortality Time: On day 28
Description: Calculation of the arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio using arterial oxygen tension measurementMeasure: Change in arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio Time: Days 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilation
Description: Measurement of arterial carbon dioxide tension, minute ventilation and calculation of ventilatory ratioMeasure: Change in ventilatory ratio Time: Days 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilation
Description: Calculation of the alveolar dead space using end-tidal carbon dioxide measurement and arterial carbon dioxide tension measurementMeasure: Change in alveolar dead space Time: Days 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilation
Description: Measurement of exhaled tidal volumeMeasure: Change in tidal volume Time: Days 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilation
Description: Calculation of the Patrick's scaleMeasure: Change in accessory respiratory muscles workload Time: Days 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilation
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports